Aurora Cannabis Inc. (the "Company" or "Aurora") (NYSE: ACB) (TSX: ACB) (Frankfurt: 21P; WKN: A1C4WM), announced today its financial and operational results for the second quarter ended December 31st, 2018.
Q2 2019 Financial and Operations Highlights
Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (NYSE: ACB) (Frankfurt: 21P; WKN: A1C4WM) announced today that its extraction technology partner, Radient Technologies ("Radient") (TSX-V: RTI; OTCQX: RDDTF), has received its Standard Processing License from Health Canada.
Aurora Cannabis Inc. (NYSE:ACB) (TSX: ACB) (Frankfurt: 21P; WKN: A1C4WM) today announced that it has closed its previously announced offering of 5.5% convertible senior notes due 2024 for gross proceeds of US$345 million (including US$45 million pursuant to the exercise of the initial purchasers' over-allotment option). The notes were issued at par value.
Earlier this week, leading Canadian cannabis producer Aurora Cannabis (ACB.TO) (ACB) announced the acquisition of Whistler Medical Marijuana Corporation (Whistler), a private organic licensed Canadian cannabis producer.
Aurora Cannabis Inc. (TSX: ACB) (NYSE: ACB) announced today that the Company has entered into a letter of intent to acquire all the issued and outstanding shares of privately held Whistler Medical Marijuana Corporation, in an all-share transaction valued at up to approximately $175 million, including certain milestone payments (the "Transaction").